BioRestorative Therapies (NASDAQ:BRTX) Issues Quarterly Earnings Results, Beats Estimates By $0.22 EPS

BioRestorative Therapies (NASDAQ:BRTX) released its earnings results on Tuesday. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.22, Zacks reports. The firm had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.30 million. BioRestorative Therapies had a negative return on equity of 93.89% and a negative net margin of 2,697.08%.

BioRestorative Therapies Price Performance

BioRestorative Therapies stock traded down $0.04 during trading hours on Thursday, reaching $1.50. The stock had a trading volume of 27,839 shares, compared to its average volume of 768,550. BioRestorative Therapies has a 52 week low of $1.03 and a 52 week high of $3.67. The company has a market cap of $10.35 million, a price-to-earnings ratio of -1.00 and a beta of 63.40. The business’s 50 day moving average price is $1.63 and its 200-day moving average price is $1.60.

Analysts Set New Price Targets

Separately, Roth Mkm raised their price target on BioRestorative Therapies from $15.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th.

About BioRestorative Therapies

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.